BioAgilytix Labs LLC, a contract research organization supporting pharmaceutical and biotech partners in all phases of drug development, has appointed Dr. Linda Robbie as chief operating officer, effective August 9, 2022.
 
For the past three years, Robbie has served as vice president and general manager of Boston operations, responsible for leading all Bioanalytical Services at BioAgilytix’s Boston, MA Laboratory. During this time, she directed all initiatives relating to science, technology, and laboratory operations.
 
Robbie has more than 25 years of experience with biomarker assay technologies, including 20 years of experience in scientific leadership positions. She was previously senior vice president of Science and Laboratory Operations at Cambridge Biomedical and joined BioAgilytix’s leadership team when the company was acquired in November 2019. She has also held senior roles with Quintiles and Immucor.
 
Commenting on her new appointment, Robbie, said: “I could not be more enthusiastic to step into this important role at BioAgilytix, as my predecessor leaves an incredible legacy of high-performing teams and growth. This is an exciting time for me but also for BioAgilytix as we chart our course forward.”
 
Robbie will continue to emphasize the importance of a strong science foundation and leverage the global laboratory’s innovation skills while keeping focused on an exceptional customer experience.
 
“Patient outcomes are always our first priority as we collaborate with our sponsors to deliver accurate and reliable data for all of the studies that we support,” she shared.
 
Euan Menzies, CEO of BioAgilytix, added: “I am delighted to welcome such a high-caliber appointment to our executive team. The skills that Linda brings to the table will be invaluable as we continue to drive forward our strategy and move towards our next phase of growth.”
 
“Since joining BioAgilytix in mid-June, I have been consistently impressed with Linda’s knowledge, expertise, and passion for delivering exceptional results. She has built a cohesive, high-performing team in Boston, and I am confident she will have a similar positive impact across the broader business.”
 
Robbie replaces Dr. Michael, who will be leaving the company at the end of the month.